Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Quercetin in mTNBC
NCT06355037Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started May 2024; status: recruiting.
02
Drugs
dasatinibquercetin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06355037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355037.